Latest Reports

The “2023 Cataract Surgical Equipment Market Report” provides in-depth analysis of the global cataract surgical equipment market, examining the market’s size and growth, as well as identifying important developments that may shape its future. The analysis focuses on the 2023 market and forecasts growth and evolution through 2028. Product demand is forecast in units and dollars, and market shares are analyzed by product category. Additionally, 20 competitors are profiled, with discussion of their products, strategic market position, background, and outlook.

The “2023 United States Retina Atlas” provides a geographic analysis of retinal treatment opportunity and key demographic metrics in 85 US metropolitan areas. Market Scope’s proprietary MedOp Index™ Analysis examines market potential and provides a benchmark against other metros. The Retina Atlas offers strategic insights into the top potential markets in the US by providing:

• Demographic information of selected metropolitan populations
• Profiles of selected metropolitan areas and applicable retinal treatment opportunity
• Current estimates for retinal surgery volume by metropolitan area
• Current estimates for retina surgeons by metropolitan area
• Comprehensive directory of US ophthalmic practices performing retinal IVTs and vitrectomies

The “2023 China Ophthalmic Market Report” covers all aspects of China’s ophthalmic market, providing a comprehensive overview of the Chinese population and economic conditions, discussing key strategic issues, studying disease prevalence, and analyzing surgical and therapeutic approaches, including both commercialized and pipeline products. The report analyzes unit demand and revenue, and forecasts future performance over the next five years. Competitor share is analyzed by product category and 32 competitors are profiled, with discussion of their products, strategic market position, background, and outlook.

The “2023 US and Western Europe Cataract Pharmaceuticals Market Report” offers an in-depth examination of the current cataract pharmaceuticals market in the United States and Western Europe and forecasts market performance over the next five years. The report analyzes the current market and forecasts units, average sales price, and revenue through 2028 by product category. It analyzes products currently on the market and examines the development pipeline, discusses the popularity of intracameral injections and fixed combination eye drops, and analyzes the roles of brand name medications, generics, and compounded formulations.

Market Scope surveyed US ophthalmic surgeons during March and April 2023 to measure perceptions of practice patterns, product market share, and plans for the coming year. We received 119 responses from doctors performing cataract procedures, representing over one thousand total doctors in single doctor and group practices.

We have conducted annual surveys of US cataract surgeons on important issues regarding practice characteristics, product preferences, surgical techniques, and practice marketing since 2001. This survey highlights practice patterns regarding presbyopic-correcting IOLs (PC-IOLs), toric IOLs, extended depth of focus (EDOF) IOLs, correction of astigmatism, femtosecond laser-assisted cataract surgery (FLACS), sugical location, interest in upcoming technology, equipment use, treatment and management of glaucoma and micro-invasive glaucoma survery (MIGS) devices and much more. It measures market share by manufacturer, product, and market segment. Leading ophthalmic firms and organizations sponsor the survey in order to better understand industry dynamics and gain important insights into surgeons’ experiences and preferences, as well as emerging trends. 

Market Scope’s 2023 Glaucoma Disease Model offers extensive country-level prevalence data and five-year forecasts for glaucoma by type and by age group for all countries with a population over a million.

This proprietary model takes into consideration the latest clinical research and demographic projections on a global scale and can be customized by geography and disease category to meet clients’ diverse needs. Disease models can be used to evaluate target markets for clinical-stage and commercial-stage products and gain insights into the volume and demographics of diseased populations.

The “2023 Glaucoma Pharmaceuticals Market Report” analyzes the global and regional markets for glaucoma pharmaceuticals, identifying important trends and key factors for future success. The report provides forecasts through 2028 for branded prostaglandins, generic prostaglandins, beta blockers, carbonic anhydrase inhibitors, alpha agonists, fixed combo drugs, NO-donating compounds, and Rho-kinase inhibitors. The report also extensively discusses pipeline products, covering over 30 drug candidates that are currently under development. Additionally, 26 glaucoma pharmaceutical companies are profiled, discussing their products, strategic market position, background, and outlook.

Market Scope’s “2022 European Five Ophthalmic Market Report” analyzes the ophthalmic market in Western Europe’s five largest economies, discussing important trends and key factors for future success in 11 ophthalmic submarkets. The report includes forecasts of disease prevalence, numbers of treatments, and technologies used in treatments. It profiles ophthalmic companies in the five markets, provides analysis of current markets, and offers five-year forecasts of market performance.

Market Scope surveyed US ophthalmic surgeons during March and April 2022 to measure perceptions of practice patterns, product market share, and plans for the coming year. We received 119 responses from doctors performing cataract procedures, representing over one thousand total doctors in single doctor and group practices.

We have conducted annual surveys of US cataract surgeons on important issues regarding practice characteristics, product preferences, surgical techniques, and practice marketing since 2001. This survey highlights practice patterns regarding presbyopic-correcting IOLs (PC-IOLs), toric IOLs, extended depth of focus (EDOF) IOLs, correction of astigmatism, femtosecond laser-assisted cataract surgery (FLACS), sugical location, interest in upcoming technology, equipment use, treatment and management of glaucoma and micro-invasive glaucoma survery (MIGS) devices and much more. It measures market share by manufacturer, product, and market segment. Leading ophthalmic firms and organizations sponsor the survey in order to better understand industry dynamics and gain important insights into surgeons’ experiences and preferences, as well as emerging trends. 

The “2022 United States Glaucoma Atlas” provides a geographic analysis of the glaucoma population and treatment opportunity in 85 US metropolitan areas. Market Scope’s proprietary MedOp Index Analysis™ analyzes market potential and provides a benchmark against other atlas metros. The atlas offers strategic insights into the top potential markets in the US, which companies often use throughout the development and commercialization processes to identify ideal clinical trial locations, develop launch strategies, define sales territories, allocate resources, and optimize sales and marketing initiatives.